FindTrial
Sign In

Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516335-27-00
Acronym
19PH226
Enrollment
90
Registered
2024-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-MAG neuropathy

Brief summary

Clinical response defined as a 4 points (or more) increase of I-RODS between baseline and 12 months

Detailed description

INCAT disability score, 6 minutes walk test, Timed 25 foot walk test, 9 hole peg test, ENMG motor sum score, ENMG sensory sum score, MUNIX sum score, Adverse events, Anti-MAG titre

Interventions

DRUGCHLORURE DE SODIUM COOPER 0
DRUG9 %
DRUGsolution injectable
DRUGMabThera 500 mg concentrate for solution for infusion

Sponsors

Centre Hospitalier Universitaire De Saint Etienne
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Clinical response defined as a 4 points (or more) increase of I-RODS between baseline and 12 months—

Secondary

MeasureTime frame
INCAT disability score, 6 minutes walk test, Timed 25 foot walk test, 9 hole peg test, ENMG motor sum score, ENMG sensory sum score, MUNIX sum score, Adverse events, Anti-MAG titre—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026